Mirabegron
Overactive bladder treatment without dry mouth.
- Starts working
- Varies
- Half-life
- About 50 hours
- In use since
- 2012
- Pregnancy
- Usually avoided
Overview
Mirabegron relaxes the bladder by a different route from antimuscarinics, so it doesn't cause dry mouth, constipation or confusion. Blood pressure should be checked because it can raise it.
Conditions it's used for
How it works
Relaxes the bladder as it fills.
Mirabegron belongs to the Beta-3 agonists. How Beta-3 agonists work: relax the bladder muscle as it fills, so it holds more.
Uses
- Overactive bladder
Available as: modified-release tablet, granules (children).
Typical dose
- Adults
- 25–50 mg once a day.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Raised heart rate
- Urinary infections
- Headache
Serious — get medical help
Uncommon, but need prompt attention
- Severely raised blood pressure
Warnings
- Not with severe uncontrolled high blood pressure
Interactions
- Digoxin — levels rise
- Metoprolol, other CYP2D6 substrates — levels rise
Pregnancy and breastfeeding
Usually avoided
Not recommended.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Myrbetriq
- United Kingdom
- Betmiga
- India
- Mirago, Mirabeg
- Australia
- Betmiga
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
Common questions
Can it be combined with an antimuscarinic?
Yes, specialists sometimes combine them for stubborn symptoms.
Do I need a prescription for Mirabegron?
Yes — Mirabegron is prescription-only in most countries.
Can I take Mirabegron during pregnancy?
Usually avoided. Not recommended. Always check with a doctor or midwife.
Related medicines
Sources and official information
- MedlinePlus (US National Library of Medicine)
- DailyMed — official US labels
- NHS medicines A–Z
- WHO ATC/DDD index — G04BD12
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.